ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sumitomo Dainippon Pharma Co., Ltd.

Business Summary

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue482,732M4,439.90M
Gross Profit341,787M3,143.56M
Operating income51,083M469.83M
Income before tax83,947M772.09M
Net income40,753M374.82M
EBITDA68,448M629.54M
Diluted EPS102.570.94
Dividends Per Share280.25
Total Assets1,252.87B11,605.55M
Total liabilities620,773M5,750.29M
Total equity529,485M4,904.68M
Operating cash flow46,128M424.26M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 403,206M 408,357M 466,838M 459,267M 482,732M
Gross Profit 293,016M 307,911M 347,955M 337,856M 341,787M
Operating income 36,929M 60,974M 79,643M 57,207M 51,083M
Income before tax 39,560M 42,781M 84,866M 65,046M 83,947M
Net income 24,697M 31,316M 53,448M 48,627M 40,753M
EBITDA 57,194M 73,687M 92,530M 71,183M 68,448M
Diluted EPS 62.16 78.82 134.53 122.39 102.57
Dividends Per Share 18 20 28 28 28
Total Assets 707,715M 779,072M 809,684M 834,717M 1,252.87B
Total liabilities 261,243M 366,804M 356,961M 336,555M 620,773M
Total equity 446,472M 412,268M 452,723M 498,138M 529,485M
Operating cash flow 52,486M 19,143M 93,420M 48,711M 46,128M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 3,357.69M 3,771.04M 4,212.10M 4,141.47M 4,439.90M
Gross Profit 2,440.08M 2,843.45M 3,139.46M 3,046.63M 3,143.56M
Operating income 307.52M 563.07M 718.58M 515.86M 469.83M
Income before tax 329.43M 395.06M 765.71M 586.55M 772.09M
Net income 205.66M 289.19M 482.24M 438.49M 374.82M
EBITDA 476.28M 680.47M 834.86M 641.89M 629.54M
Diluted EPS 0.51 0.72 1.21 1.10 0.94
Dividends Per Share 0.14 0.18 0.25 0.25 0.25
Total Assets 6,296.67M 6,991.58M 7,613.38M 7,541.37M 11,605.55M
Total liabilities 2,324.32M 3,291.78M 3,356.47M 3,040.65M 5,750.29M
Total equity 3,972.34M 3,699.79M 4,256.91M 4,500.50M 4,904.68M
Operating cash flow 437.07M 176.77M 842.89M 439.25M 424.26M

Valuation Measures

Mar 2020
PER13.67
ROA3.90%
ROE7.93%
Operating margin10.58%
Profit margin8.44%

Key executives

  • President & Representative Director: Hiroshi Nomura
  • GM-Production, Head-Research & Technology: Yoshiharu Ikeda
  • Executive Officer: Shigeyuki Nishinaka
  • Executive Officer: Antony Loebel
  • Director & Managing Executive Officer: Toru Kimura

Shareholders

  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Inabata & Co., Ltd. (4.6%)
  • Nomura Asset Management Co., Ltd. (3.6%)
  • Nippon Life Insurance Co. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.8%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Daiwa Asset Management Co. Ltd. (1.7%)
  • Sumitomo Life Insurance Co. (1.4%)
  • The Vanguard Group, Inc. (1.2%)
  • MS&AD Insurance Group Holdings, Inc. (1.0%)

Contact Details

Related Companies

  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sumitovant Biopharma Ltd. (London)
  • Sumitovant Biopharma Ltd.
  • Sumitomo Dainippon Pharma Pension Fund
  • Urovant Sciences Ltd.
  • Myovant Sciences Ltd.
  • Dainippon Sumitomo Pharma America Holdings, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co. Ltd.
  • Sunovion Pharmaceuticals Europe Ltd.
  • Sumitomo Dainippon Pharma Trust
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.

Competitors

  • VistaGen Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.
  • Alkermes Plc
  • Axovant Gene Therapies Ltd.
  • Intra-Cellular Therapies, Inc.
  • Xenon Pharmaceuticals Inc.
  • Karuna Therapeutics, Inc.
  • Innoviva, Inc.
  • Marinus Pharmaceuticals Inc
  • Adamas Pharmaceuticals, Inc.
  • ERYTech Pharma SA
  • Verona Pharma plc
  • Voyager Therapeutics, Inc.
  • Acorda Therapeutics, Inc.
  • SELLAS Life Sciences Group, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Gossamer Bio, Inc.
  • Aravive, Inc.
  • BioLineRX Ltd.
  • Cyclacel Pharmaceuticals, Inc.
  • Neos Therapeutics, Inc.
  • OptiNose, Inc.
  • Qurient Co., Ltd.
  • SCYNEXIS, Inc.
Last Updated on 25 Sep, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media